AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing
In further legal action against drugmakers allegedly over pricing AIDS drugs in the USA, the AIDS Healthcare Foundation (AHF) has filed a law suit in the Superior Court of the State of California alleging that between 2005 and 2013, Abbott Laboratories (NYSE ABT) and its spinoff AbbVie (NYSE: ABBV) failed to provide legally required discounts for HIV drugs, overcharging the AHF by more than $2 million during the eight year period.
Abbott is bound by contractual obligations to sell drugs, including AIDS drugs, to AHF and others at discounted prices under the 340B discount drug program, a federal drug discount program designed to stretch scarce government resources as far as possible for safety net health care providers such as the AHF. The AHF last month took similar action against Johnson & Johnson (The Pharma Letter November 1).
Action follows company refusal to reimburse excess amounts
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze